Cadence Pharmaceuticals, (FRA:QEW) Enterprise Value : €887.38 Mil (As of May. 25, 2024)

Cadence Pharmaceuticals, Enterprise Value Chart

Cadence Pharmaceuticals, Annual Data
	Trend	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13
Enterprise Value		Get a 7-Day Free Trial					281.64	224.25	-	-	590.09

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
Enterprise Value	Get a 7-Day Free Trial															-	319.77	451.55	395.37	590.09

Competitive Comparison of Cadence Pharmaceuticals,'s Enterprise Value

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cadence Pharmaceuticals,'s Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Enterprise Value distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Enterprise Value falls into.

Cadence Pharmaceuticals, Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Cadence Pharmaceuticals,'s Enterprise Value for the fiscal year that ended in Dec. 2013 is calculated as

Cadence Pharmaceuticals,'s Enterprise Value for the quarter that ended in Dec. 2013 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadence Pharmaceuticals,  (FRA:QEW) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Cadence Pharmaceuticals,'s EV-to-EBIT for today is

Cadence Pharmaceuticals,'s current Enterprise Value is €887.38 Mil.
Cadence Pharmaceuticals,'s EBIT for the trailing twelve months (TTM) ended in Dec. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.89 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Cadence Pharmaceuticals,'s EV-to-EBITDA for today is:

Cadence Pharmaceuticals,'s current Enterprise Value is €887.38 Mil.
Cadence Pharmaceuticals,'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.78 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Cadence Pharmaceuticals,'s EV-to-Revenue for today is:

Cadence Pharmaceuticals,'s current Enterprise Value is €887.38 Mil.
Cadence Pharmaceuticals,'s Revenue for the trailing twelve months (TTM) ended in Dec. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €84.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadence Pharmaceuticals, Enterprise Value Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, (FRA:QEW) Business Description